PLAT and stroke disorder: Basic research reveals that the protease inhibitor Bortezomib (VELCADE) combined with tPA suppresses the TLR4/IRAK1 pathway in endothelial cells via miR-146a upregulation, reducing cerebral infarct volume by 46% in rat stroke models while reversing tPA-induced vascular inflammation (197).